Infliximab (Remicade, Schering-Plough Pharma Inc.), a chimeric IgG monoclonal antibody, was the first commercially available drug targeting TNF-α.16 Etanercept (Enbrel, Whiet Pharmaceuticals Inc.),17 a p75 TNF-α receptor fusion protein,17 is no longer used in ocular inflammations since it has been proven to exacerbate the uveitis severity.18 This evidence concerns the gene TNF and uveitis.